Skip to main content
    N

    Nektar Therapeutics (NKTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $36.44
    -0.83 (-2.23%)

    Market Cap: $1.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nektar Therapeutics (NKTR) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Nektar Therapeutics (NKTR) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Nektar Therapeutics reported EPS of -$1.63, above the -$2.16 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +11.57%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.53
    Range-$3.43 - -$1.79
    17 analysts
    Revenue Consensus
    $9.40M
    Range$7.45M - $12.60M
    17 analysts

    Next Report

    NKTR has an expected report date of Mar 10, 2027.

    NKTR Earnings Call

    The latest NKTR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, NKTR beat 29, missed 10 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $9.39M, down 20.4% from $11.79M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.63-$2.16-$3.07 - -$1.71+24.54%BeatN/A152 up, 0 downNov 12, 2026$9.39M
    Jun 30, 2026-$1.23-$2.06-$2.74 - -$1.72+40.29%BeatN/A42 up, 0 downAug 13, 2026$10.13M
    Mar 31, 2026-$1.78-$1.48-$1.83 - -$1.22-20.27%MissN/A4N/AMay 7, 2026$10.86M
    Dec 31, 2025-$1.78-$2.47N/A+28.05%BeatN/A20 up, 0 downMar 12, 2026$21.81M
    Sep 30, 2025-$1.87-$2.79-$3.23 - -$2.32+32.97%BeatN/A31 up, 0 downNov 6, 2025$11.79M
    Jun 30, 2025-$2.95-$3.13-$3.43 - -$2.81+5.75%BeatN/A20 up, 1 downAug 7, 2025$11.18M
    Mar 31, 2025-$3.61-$2.82-$3.15 - -$2.47-28.01%MissN/A31 up, 0 downMay 8, 2025$10.46M
    Dec 31, 2024-$0.15-$0.13N/A-15.38%MissN/A21 up, 0 downMar 12, 2025$29.18M
    Sep 30, 2024-$2.65-$3.09-$3.90 - -$2.40+14.24%BeatN/A70 up, 0 downNov 7, 2024$24.12M
    Jun 30, 2024-$2.81-$3.01-$3.60 - -$2.55+6.64%BeatN/A50 up, 0 downAug 8, 2024$23.49M
    Mar 31, 2024-$2.76-$3.07-$3.30 - -$2.55+10.10%BeatN/A30 up, 0 downMay 9, 2024$21.64M
    Dec 31, 2023-$0.22-$0.21-$0.33 - -$0.15-4.76%MissN/A50 up, 0 downMar 4, 2024$23.89M
    Sep 30, 2023-$2.85-$2.40-$4.05 - -$2.25-18.75%MissN/A71 up, 0 downNov 7, 2023$24.14M
    Jun 30, 2023-$4.05-$3.30-$6.30 - -$3.30-22.73%MissN/A80 up, 0 downAug 8, 2023$20.50M
    Mar 31, 2023-$3.75-$3.59-$4.95 - -$2.40-4.46%MissN/A70 up, 0 downMay 9, 2023$21.59M
    Dec 31, 2022-$0.32-$0.45-$0.55 - -$0.24+28.89%BeatN/A101 up, 0 downFeb 28, 2023$22.02M
    Sep 30, 2022-$4.65-$6.54-$9.90 - -$4.35+28.90%BeatN/A100 up, 0 downNov 3, 2022$23.63M
    Jun 30, 2022-$12.75-$15.25-$17.39 - -$9.45+16.39%BeatN/A100 up, 0 downAug 4, 2022$21.59M
    Mar 31, 2022-$7.35-$10.01-$13.34 - -$7.35+26.57%BeatN/A115 up, 2 downMay 5, 2022$24.82M
    Dec 31, 2021-$0.79-$0.81-$0.89 - -$0.71+2.47%BeatN/A131 up, 0 downFeb 28, 2022$25.01M
    Sep 30, 2021-$10.50-$12.09-$13.19 - -$10.94+13.15%BeatN/A113 up, 0 downNov 4, 2021$24.92M
    Jun 30, 2021-$10.35-$10.98-$11.69 - -$10.04+5.74%BeatN/A12N/AAug 5, 2021$28.33M
    Mar 31, 2021-$10.20-$10.90-$12.59 - -$8.70+6.42%BeatN/A10N/AMay 6, 2021$23.65M
    Dec 31, 2020-$0.65-$0.68-$0.80 - $0.04+4.41%BeatN/A13N/AFeb 25, 2021$23.46M
    Sep 30, 2020-$9.15-$11.28-$12.59 - -$7.65+18.88%BeatN/A13N/ANov 5, 2020$30.03M
    Jun 30, 2020-$6.75-$10.32-$11.24 - -$8.85+34.59%BeatN/A14N/AAug 6, 2020$48.85M
    Mar 31, 2020-$0.53-$0.77-$0.88 - -$0.43+31.17%BeatN/A14N/AMay 7, 2020$50.57M
    Dec 31, 2019-$9.60-$10.30-$11.39 - -$7.95+6.80%BeatN/A13N/AFeb 27, 2020$33.86M
    Sep 30, 2019-$8.40-$10.83-$12.29 - -$9.75+22.44%BeatN/A13N/ANov 6, 2019$29.22M
    Jun 30, 2019-$9.45-$12.00-$12.89 - -$11.24+21.25%Beat-111.8%11N/AAug 8, 2019$23.32M
    Mar 31, 2019-$10.20-$11.34-$12.29 - -$5.10+10.05%BeatN/A11N/AMay 8, 2019$28.22M
    Dec 31, 2018-$0.57-$0.65-$0.80 - $0.65+12.31%BeatN/A11N/AFeb 28, 2019$39.83M
    Sep 30, 2018-$8.40-$9.46-$10.94 - -$7.80+11.21%Beat-251.4%8N/ANov 7, 2018$27.76M
    Jun 30, 2018$79.95$79.30$64.77 - $88.31+0.82%BeatN/A10N/AAug 8, 2018$1.09B
    Mar 31, 2018-$9.00-$8.20-$10.49 - $82.16-9.76%MissN/A10N/AMay 10, 2018$38.02M
    Dec 31, 2017-$0.11-$0.35-$0.43 - -$0.26+68.57%BeatN/A7N/AMar 1, 2018$95.47M
    Sep 30, 2017$5.55$3.36-$3.00 - $4.05+65.18%BeatN/A7N/ANov 7, 2017$152.93M
    Jun 30, 2017-$5.85-$5.45-$6.30 - -$4.05-7.34%MissN/A7N/AAug 8, 2017$34.59M
    Mar 31, 2017-$0.42-$0.42N/A0.00%In lineN/AN/AN/AMay 9, 2017$24.73M
    Dec 31, 2016-$4.20-$4.01N/A-4.74%MissN/AN/AN/AMar 1, 2017$37.45M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$10.21, after -$8.37 the year before. It was -$16.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$10.21N/A
    Dec 31, 2024-$8.37N/A
    Dec 31, 2023-$10.87N/A
    Dec 31, 2022-$25.07N/A
    Dec 31, 2021-$31.84N/A
    Dec 31, 2020-$17.08N/A
    Dec 31, 2019-$37.65-160.7%
    Dec 31, 2018$61.98N/A
    Dec 31, 2017-$0.83N/A
    Dec 31, 2016-$16.50N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,67818
    2026Q2Jun 30, 20266,44216
    2026Q1Mar 31, 20266,66816
    2025Q4Dec 31, 20257,22514
    2025Q3Sep 30, 20256,55213
    2025Q2Jun 30, 20257,41513
    2025Q1Mar 31, 20257,31413
    2024Q3Sep 30, 20245,84912

    2026Q3 Earnings Call

    Opening remarks

    Vivian Wu Investor Relations Thank you, Crystal, and good afternoon, everyone. Thank you for joining us today. On today's call, you will hear from Howard Robin, our President and Chief Executive Officer; Dr. Mary Tagliaferri, our Chief Medical Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Linda Rubinstein, our Chief Financial Officer. Before we begin, I would like to remind you that we will be making forward-looking statements regarding our business, including statements related to the therapeutic and commercial potential and development plans for rezpegaldesleukin, the timing and execution of clinical trials, expectations for clinical data and regulatory filings, potential strategic partnering activities, financial guidance, and other statements regarding the future of our business. Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult to predict, many of which are outside of our control. For a discussion of these risks and uncertainties, please refer to our filings with the SEC, including our most recent Form 10-K and subsequent filings. We undertake no obligation to update these forward-looking statements except as required by law. A live webcast and replay of this call will be available on the Investor Relations section of our website at nektar.com. With that, I'll turn the call over to Howard.

    Howard W. Robin President and Chief Executive Officer Thank you, Vivian. Thank you to everyone for joining us this afternoon. Q3 was a transformative quarter for Nektar as we advanced REZPEG into phase III studies. Building on its compelling phase II results across two key immune dermatology indications, we initiated a comprehensive phase III plan for REZPEG in both atopic dermatitis and alopecia areata. Our global phase III studies in atopic dermatitis have started, and our phase III study in alopecia areata is on track to start in December, earlier than was originally planned. As we said last quarter, we anticipate our first top-line data readouts for the atopic dermatitis studies will be in the summer of 2028. In the U.S. alone, over 31 million people are estimated to have eczema. The U.S. market for treatments for this chronic disorder is expected to grow to over $30 billion by 2033. Now, in spite of a number of approved systemic therapies to treat patients with moderate to severe atopic dermatitis, only 1 in 4 patients today receive a systemic treatment. Atopic dermatitis is a highly heterogeneous disease, meaning the biology driving the underlying disease state can be complex and can vary significantly from one patient to another. The current approved biologics target one single inflammatory pathway, specifically the type 2 inflammatory pathway, and mostly through IL-13 cytokine blocking.

    Frequently Asked Questions About NKTR

    When is Nektar Therapeutics's next earnings date?

    Nektar Therapeutics's next earnings report is expected for Mar 10, 2027.

    Did NKTR beat earnings estimates last quarter?

    Yes. Nektar Therapeutics reported EPS of -$1.63 for the quarter ended Sep 30, 2026, above the -$2.16 estimate, a 24.54% surprise.

    What EPS do analysts expect from NKTR next quarter?

    The consensus EPS estimate for Nektar Therapeutics for the quarter ending Dec 31, 2026 is -$2.53 from 17 analysts, with estimates from -$3.43 to -$1.79.

    How often does NKTR beat earnings estimates?

    Nektar Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +8.49%.